LGT Fund Management Co Ltd. Buys New Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

LGT Fund Management Co Ltd. purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 10,070 shares of the biopharmaceutical company's stock, valued at approximately $2,370,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC lifted its stake in shares of Alnylam Pharmaceuticals by 62.2% in the third quarter. Allspring Global Investments Holdings LLC now owns 420 shares of the biopharmaceutical company's stock valued at $116,000 after buying an additional 161 shares during the period. Wealth Enhancement Advisory Services LLC lifted its position in shares of Alnylam Pharmaceuticals by 56.2% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 6,454 shares of the biopharmaceutical company's stock worth $1,775,000 after acquiring an additional 2,323 shares during the period. New York State Teachers Retirement System acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $1,453,000. Farther Finance Advisors LLC increased its position in shares of Alnylam Pharmaceuticals by 95.4% during the third quarter. Farther Finance Advisors LLC now owns 211 shares of the biopharmaceutical company's stock valued at $58,000 after purchasing an additional 103 shares during the period. Finally, Robeco Institutional Asset Management B.V. raised its stake in shares of Alnylam Pharmaceuticals by 48.1% in the third quarter. Robeco Institutional Asset Management B.V. now owns 73,568 shares of the biopharmaceutical company's stock valued at $20,233,000 after purchasing an additional 23,898 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 1,752 shares of the firm's stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $251.00, for a total transaction of $439,752.00. Following the sale, the chief marketing officer now directly owns 15,705 shares in the company, valued at approximately $3,941,955. This trade represents a 10.04 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Phillip A. Sharp sold 11,250 shares of the company's stock in a transaction that occurred on Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total transaction of $3,093,750.00. The disclosure for this sale can be found here. Insiders have sold a total of 72,986 shares of company stock valued at $20,397,849 over the last three months. 1.50% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Wolfe Research cut shares of Alnylam Pharmaceuticals from a "peer perform" rating to an "underperform" rating in a research note on Tuesday, November 12th. Piper Sandler reissued an "overweight" rating and issued a $296.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. Chardan Capital reaffirmed a "buy" rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. StockNews.com lowered Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, January 9th. Finally, Scotiabank reduced their target price on shares of Alnylam Pharmaceuticals from $310.00 to $300.00 and set a "sector outperform" rating on the stock in a research note on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $304.26.

Alnylam Pharmaceuticals Trading Down 0.4 %

NASDAQ:ALNY traded down $1.10 during mid-day trading on Thursday, hitting $248.13. The company had a trading volume of 550,873 shares, compared to its average volume of 791,198. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The firm has a market cap of $32.12 billion, a P/E ratio of -114.35 and a beta of 0.35. The business's fifty day moving average is $254.46 and its two-hundred day moving average is $261.81.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). As a group, research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.